Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies by Schicho, Andreas et al.
© 2018 Schicho et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
OncoTargets and Therapy 2018:11 345–350
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
345
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S147852
Safety and efficacy of transarterial 
chemoembolization with degradable starch 
microspheres (DsM-Tace) in the treatment 
of secondary liver malignancies
andreas schicho1
Philippe l Pereira2
Katharina Michalik1
lukas P Beyer1
christian stroszczynski1
Philipp Wiggermann1
1Department of radiology, University 
hospital regensburg, regensburg, 
2Department of radiology, Minimal-
invasive Therapies and nuclear 
Medicine, slK Kliniken heilbronn, 
heilbronn, germany
Purpose: To evaluate the safety and efficacy of degradable starch microspheres (DSM) as 
embolic agents in transarterial chemoembolization (TACE) in the treatment of secondary liver 
metastases.
Methods: This was a national, multicenter observational study. Primary endpoints were safety 
and treatment response according to Modified Response Evaluation Criteria in Solid Tumors 
(mRECIST) criteria.
Results: A total of 77 DSM-TACE procedures were performed in 20 patients. Minor immedi-
ate adverse events (AEs) were epigastric pain with an incidence of 45.5% (35/77), and nausea 
and vomiting at an incidence of 23.4% (18/77). Delayed minor AEs were epigastric pain in 
13/77 (16.9%) treatments and nausea and vomiting in 10 (13.0%) treatments. No severe AEs 
were documented. Therapeutic efficacy of DSM-TACE procedures according to mRECIST was 
as follows: complete response 0/77, partial response 17/77, stable disease 33/77 and progres-
sive disease 6/77, no data was available for 21/77 treatments. Overall, objective response was 
achieved in 8 of 20 patients (40.0%).
Conclusion: DSM as embolic agent for TACE is safe in the treatment of liver metastases. 
An objective response in 40.0% of patients and disease control in 64.9% of procedures was 
achieved, and this should lead to further evaluation of DSM-TACE as treatment option for 
nonresectable liver metastases.
Keywords: TACE, DSM, safety, efficacy, metastases, secondary malignancies
Introduction
A large percentage of hepatic malignancies are secondary metastases. With hepatic 
metastatic seeding, solid organ cancers mostly disqualify for curative treatment 
approaches. Evidence for curability of hepatic metastases is emerging, limited to patients 
with isolated liver metastases, usually further restricted to non-bilobar disease;1,2 thus, 
less than 1/5 of patients with secondary liver malignancy qualify for curative treat-
ment at the time of initial diagnosis.3 Accordingly, the majority of patients face sparse 
options for targeted therapy of hepatic metastases; within the cluster of interventional 
transarterial therapies, degradable starch microspheres – transarterial chemoemboliza-
tion (DSM-TACE) is one option in palliative treatment besides, eg, radioembolization 
using Yttrium90 or hepatic arterial infusion of chemotherapeutic agents. The injec-
tion of a chemotherapeutic agent in TACE, mixed with an embolic material such as 
Lipiodol, DSM, or drug-eluting beads, aims at reaching a steep drug concentration 
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gradient within the tumor and low systemic concentrations.4 
Thus, systemic side effects are limited, while higher drug 
dosages favor the local antitumor efficacy. As for all tran-
sarterial therapies, data on DSM-TACE is sparse since 
treatment regimes for hepatic metastasis of advanced-stage 
solid tumors vary widely. Furthermore, with TACE being 
one treatment option, it is not standardized. TACE-caused 
complications can be severe, eg, ascites, acute liver and/or 
renal failure, hepatic encephalopathy, and gastrointestinal 
bleedings. Minor adverse events (AEs) after TACE are 
summarized as postembolization syndrome, it comprises 
upper right quadrant abdominal pain, fever, and nausea and 
vomiting within 24 hours post TACE. Despite the palliative 
treatment situation, treatment regimes are required which 
reduce side effects and improve tumor response rates.
This study reports results of a national multicenter 
observational study on safety and efficacy of DSM-TACE 
in secondary liver malignancies as an interventional, locore-
gional treatment option.
Methods
Patients
All patients received standard of care, and treatment regimes 
were defined in an interdisciplinary tumor conference. Patients 
aged 18 years and older with a secondary liver malignancy 
of any stage not suitable for resection or any other curative 
treatment strategy were eligible for inclusion, independent 
of type, stage, and pretreatment of the primary malignancy. 
Both nodular and infiltrative growth, as well as single-lobar 
and bilobar disease were suitable for inclusion. Excluded from 
study participation were patients with prior chemoemboliza-
tion, enrollment in any other clinical trial, and/or having other 
contraindications against DSM-TACE such as lacking a safe 
arterial access to the intrahepatic malignancy.
Approval by the local ethics committee (University of 
Regensburg) was waived due to the observational nature 
of the study, and it was conducted in accordance with the 
Declaration of Helsinki, the International Conference on 
Harmonization Guideline on Good Clinical Practice, and 
national laws and regulations where applicable. Written 
informed consent for DSM-TACE was obtained at least 
24 hours prior to embolization.
study design
This was a national, multicenter observational study on 
safety and efficacy of DSM-TACE in palliative treatment 
for secondary liver malignancies. Recruitment period for the 
study was from January 2010 to June 2014.
safety and toxicity
The key point of the observational study was to evaluate 
DSM-TACE treatment-emergent adverse events (TEAEs). 
Separately registered were side effects within 24 hours of a 
DSM-TACE procedure and between two treatments (6 weeks 
apart), all according to the CTCAE V4.0 classification of 
acute and subacute toxic side effects listing both treatment-
emergent serious AEs and TEAEs.
Efficacy
DSM-TACE efficacy in secondary liver malignancy treat-
ment was rated according to mRECIST response criteria for 
the assessment of tumor necrosis in locoregional therapies 
6 weeks after TACE.5,6 Using mRECIST first hand,7 complete 
remission is defined as no malignancy left, partial remission 
as tumor decline .30%, stable disease as a tumor neither of 
decline .30% nor progress .20%. Tumor progress (pro-
gressive disease) is defined by a growth of .20%. Objec-
tive response rate (ORR) is complete remission + partial 
remission, and disease control is ORR + stable disease, as 
reported before.8
DsM-Tace
After staging (magnetic resonance imaging [MRI] and/or 
computed tomography [CT]), patients received DSM-TACE 
as outlined below. Six weeks later, in a restaging including 
MRI and/or CT, a decision was made if another TACE 
was suitable.
Femoral artery was punctured in all DSM-TACE pro-
cedures; selective (A. hepatica propria, A. hepatica sin., 
A. hepatica dex.) or superselective catheterization was used, 
at the interventionalist’s discretion with respect to tumor 
burden, hepatic vascular status, and patient characteristics.
EmboCept S DSM 35/50 (PharmaCept GmbH, Berlin, 
Germany) is a short-term embolizate made of degrad-
able starch microspheres with an average diameter of 
50 micrometers. They have a half-life of about 35–50 minutes, 
both in vivo and in vitro. A specific side effect of all vascu-
lar occlusion strategies such as TACE is a backflow of the 
embolizate to nontarget regions, causing ischemia and severe 
pain. DSM lowers the risk of severe organ damage due to 
its self-limiting degradation; partial resumption of the blood 
flow will be evident after about 10–15 minutes.4
Preparation and dosage of DSM was chosen per the 
manufacturer’s recommendation; choice of chemotherapeutic 
agent or a combination of up to three drugs were up to the 
individual patient and case characteristics. DSM allows the 
use of a variety of coadministered contrast agents.
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imaging
Within this observational study, imaging modality for staging 
of intrahepatic lesions and assessment of therapeutic efficacy 
was chosen at the interventionalist’s discretion. Before and 
after DSM-TACE, all patients underwent CT and/or MRI 
imaging using a multiphase liver imaging protocol. The 
same imaging modalities were used throughout each patient’s 
participation in the study to enable a reliable rating according 
to mRECIST as outlined before.
statistical analysis
For statistical analysis, GraphPad Prism ver. 5.00a for Mac 
(GraphPad Software, San Diego, CA, USA) was used. 
Arising from the observational characteristic of the reported 
study, descriptive statistics were used.
Results
In our national, multicenter observational study on safety and 
efficacy of DSM-TACE in the treatment of secondary liver 
malignancies, we included 20 patients between January 2010 
and October 2014. They received a total of 77 DSM-TACE 
procedures. Data on baseline characteristics of patients, 
pretreatment, and disease extent is summarized in Table 1. 
Data on primary malignancies is provided in Figure 1.
DsM-Tace procedure characteristics
DSM-TACE was used in a palliative treatment setting in all 
cases. Details on TACE procedure and chemotherapeutics 
used are shown in Tables 2 and 3, respectively.
safety
Immediate minor AEs were as follows: nausea and vomiting 
occurred in 18 out of 77 treatments (23.4%). In 35 treatments 
(45.5%), moderate, transient epigastric pain was registered. 
After 4 DSM-TACE procedures (5.2%), body temperature 
was elevated; after 2 procedures (2.6%), sweating occurred; 
and after 1 procedure (1.3%), the feeling of abdominal pres-
sure was registered. Delayed minor AEs were as follows: 
13 (16.9%) treatments were followed by epigastric pain, 
and in between 10 treatments (13.0%) nausea and vomiting 
was reported. There were also 2 reports (2.6%) of diarrhea, 
6 (7.8%) of fever, 5 (6.5%) of shivering, and 1 (1.3%) of an 
ulcer in between treatments. No immediate or delayed severe 
AEs were recorded. Overall, minor immediate AE occurred 
in 48/77 (62.3%) treatments and minor delayed AE in 18/77 
(23.4%) treatments (Figure 2).
Efficacy and tumor response
In a total of 77 DSM-TACE procedures with clinical and 
imaging follow-up, progress was registered after 6 proce-
dures (7.8%), 33 (42.9%) showed no change according to Table 1 Baseline characteristics of patients, pretreatment, and 
disease extent
Characteristics n
age (mean ± sD; min; max) 60.7±8.8; 37; 
75 years
Pretreatment
surgery of primary tumor 14/20 (70.0%)
surgery + chemotherapy of hepatic metastases 3/20 (15.0%)
chemotherapy 10/20 (50.0%)
no pretreatment of hepatic metastases 9/20 (45.0%)
Disease extent
,4 hepatic metastases 4/20 (20.0%)
$4 hepatic metastases 11/20 (55.0%)
number of metastases unknown 5/20 (25.0%)
left lobe 0/20 (0%)
right lobe 5/20 (25.0%)
Bilobar; no data 12/20 (60.0%); 
3/20 (15.0%)
Infiltrative growth 3/20 (13.0%)
nodular growth 16/20 (80.0%)
Infiltrative and nodular growth 1/20 (5.0%)
Abbreviations: sD, standard deviation; min, minimum; max, maximum.
Table 2 Details on Tace procedures
Catheter position n
ahP 40/77 (51.9%)
ahD 8/77 (10.4%)
ahs 3/77 (3.9%)
ahD + ahs 17/77 (22.1%)
ahP + ahD + ahs 1/77 (1.3%)
superselective 8/77 (10.4%)
DsM dose (mg) 232.6±161.3
contrast agent (ml) 30.2±40.3
injection time of cTX (min) 10.5±9.3
Tace sequence
cTX and DsM combined 33/77 (42.9%)
cTX prior to DsM 34/77 (44.2%)
DsM prior to cTX; no data 7/77 (9.1%); 3/77 (3.9%)
Abbreviations: Tace, transarterial chemoembolization; ahP, a. hepatica propria; 
ahD, a. hepatica dextra; ahs, a. hepatica sinistra; cTX, chemotherapeutic agent; 
DsM, degradable starch microspheres.
?
??????
? ?? ?? ??? ?????????????
??????????????????
???????????????
????????????????????
??????????
Figure 1 Primary malignancies with hepatic metastases. 
Abbreviation: cUP, cancer of unknown primary.
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mRECIST, and partial response was achieved in 17 proce-
dures (22.1%). No case of complete response was reported. 
No data was available for 21 procedures (27.3%). Thus, the 
ORR for TACE procedures was 22.1%; disease control was 
achieved in 64.9% of TACE procedures. All cases of objec-
tive response were attributable to 8 of 20 (40.0%) patients 
included.
Discussion
Minimally invasive locoregional approaches are of special 
interest in the treatment of secondary liver malignancies, 
since 80% of patients disqualify for surgical and potentially 
curative treatment options due to disease extent at the time 
of diagnosis.9 DSM-TACE is one option for the palliative 
treatment of secondary liver malignancies.
TACE yields high local chemotherapeutic concentrations 
with a steep gradient to healthy liver parenchyma due to the 
specific architecture of hepatic blood supply.10 Low levels 
of free circulating chemotherapeutics allow for detaining 
and minimizing systemic side effects. Thus, the aim of this 
national multicenter observational study regarding DSM-
TACE for the treatment of secondary liver malignancies was 
to assess safety and efficacy of this treatment regime.
While reports on TACE regimes using nondegradable 
microspheres (eg, drug-eluting beads) as embolic agent 
are increasing, studies on DSM are limited. Studies to be 
found are mostly centered around hepatic metastases of 
colorectal carcinoma, since up to 80% of secondary liver 
malignancies are of gastrointestinal origin due to its portal 
venous drainage.11 Nishiofuku et al12 reported a response rate 
for DSM-TACE with cisplatin (80 mg/m2 BSA) of 61.1% 
(11/18 patients) after failure of systemic folinic acid, fluoru-
racil, oxaliplatin regime in hepatic metastases of colorectal 
carcinoma. Besides others, nausea, vomiting, and pain were 
reported in 45.8%, 50.0%, and 45.8% of patients, respec-
tively. As severe AEs, thrombocytopenia, cholecystitis, and 
high-grade aspartate transaminase elevation were found in 
12.5%, 4.2%, and 33.3% of patients, respectively. A compa-
rable response rate of 59% was reported by Tsuchiya et al,13 
in 2007, likewise in TACE of hepatic metastases of colorectal 
carcinoma. Further comparable results of response rates after 
DSM-TACE are summarized in Table 4.14
The results of our study are in line with previously 
published data. With regard to safety, we report transient 
epigastric pain to be the dominant TEAE with an incidence of 
45.5%. Nausea and vomiting followed with a rate of 23.4%. 
Table 3 chemotherapy regimes used in DsM-Tace
Regimes n
Mitomycin, cisplatin, gemcitabin 15
Mitomycin, Oxaliplatin, gemcitabin 6
Mitomycin, Oxaliplatin, irinotecan 2
Mitomycin, cisplatin, irinotecan 6
Mitomycin, Oxaliplatin 6
Mitomycin, gemcitabin 2
Oxaliplatin, gemcitabin 1
Oxaliplatin, irinotecan 1
epirubicin 24
Doxorubicin 6
irinotecan 4
gemcitabin 2
Mitomycin; no data 1; 1
Abbreviations: DsM, degradable starch microspheres; Tace, transarterial 
chemoembolization.
Table 4 Orrs in DsM-Tace in current literature 
Author Year Number of 
patients
Number of 
responders
ORR
Wollner et al18 1986 15 3 20%
lorenz et al19 1989 11 4 36%
Taguchi et al20 1992 10 4 40%
Fujimoto et al21 1993 13 10 77%
civalleri et al22 1994 23 10 44%
Voigt et al23 2002 10 3 30%
Wasser et al14 2005 21 3 14%
Tsuchiya et al13 2007 27 16 59%
nishiofuku et al12 2013 18 11 61%
current study 2017 20 8 40%
Abbreviations: Orr, objective response rate; DsM, degradable starch 
microspheres; Tace, transarterial chemoembolization.
?
???????????????? ??????????????
??
???
??
??
?????????
Figure 2 immediate (,24 h) and delayed (.24 h) aes in DsM-Tace.
Note: n, number of DsM-Tace procedures.
Abbreviations: aes, adverse events; DsM, degradable starch microspheres; Tace, 
transarterial chemoembolization.
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Both symptoms are known to occur with high incidence in 
TACE procedures. Yet, standards for treatment are missing. 
A profound antiemetic and analgesic therapy should be able 
to ameliorate a significant proportion of these TEAEs.15,16 
No severe TEAEs were documented. From 20 patients fol-
lowed until drop-out, none discontinued TACE treatment 
due to primary treatment-emergent reasons, emphasizing 
the high tolerance of DSM-TACE.
With DSM-TACE, an objective response was achieved in 
40.0% of cases, with partial response in 22.1% of procedures 
and no further progress after 42.9% of procedures, summing 
up to 64.9% of procedures achieving disease control. These 
results should be valued as promising, keeping in mind that 
DSM-TACE is a minimally invasive, palliative treatment 
option in a patient cohort showing a high disease burden 
with associated comorbidities.17
The significance of the presented results must be evalu-
ated considering the study’s limitations. The small sample 
size and the heterogeneous nature of the primary malignancy 
are evident as is the nonstandardized TACE treatment pro-
tocol including diagnostic pathways for follow-up imaging. 
Further clinical studies are needed to compare the efficacy 
including long-term survival and/or progression-free survival 
in comparison to the standard TACE with Lipiodol.
Conclusion
In summary, TACE with DSM as embolic agent is safe to use 
in the treatment of secondary liver malignancies not suitable 
for surgery. Efficacy is promising, with disease control in 
64.9% of procedures and an objective response in 40.0% of 
patients. Further reduction of AEs and increase in efficacy 
should be achievable by standardizing both the DSM-TACE 
treatment regime as well as the accompanying side medica-
tions prescribed (eg, analgesics, antiemetics) according to 
well-established standards.
Main points
•	 DSM can be used as embolic agent in TACE of hepatic 
malignancies
•	 DSM-TACE is safe in the treatment of liver metastases 
taking into consideration adverse and severe AEs
•	 DSM-TACE shows promising efficacy in the treatment 
of liver malignancies in a variety of primary tumors.
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